CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $267.47M, lower than 95% of all stocks globally
- PositionOperating margin is -4834.6%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
267.47MUSDvs all stocks (USD)
Revenue (TTM)
5.74MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2640xvs all stocks
52-Week Change
12.21%vs all stocks
Market Capitalization
267.47MUSDvs all stocks (USD)
Enterprise Value
43.16MUSDvs all stocks (USD)
Forward P/E
-2.12xvs Biotechnology peers
Price to Sales (TTM)
46.61xvs Biotechnology peers
Price to Book (MRQ)
0.9166xvs Biotechnology peers
Enterprise to Revenue
7.52xvs Biotechnology peers
Enterprise to EBITDA
-0.2500xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-4834.63%vs Biotechnology peers
Return on Assets (TTM)
-26.84%vs Biotechnology peers
Return on Equity (TTM)
-48.28%vs Biotechnology peers
Revenue (TTM)
5.74MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1380USDUpdated Jul 19, 2026Quarterly Revenue Growth
-95.70%vs Biotechnology peers
Gross Profit (TTM)
-135.81MUSDvs all stocks (USD)
EBITDA (TTM)
-172.56MUSDvs all stocks (USD)
Net Income (TTM)
-166.12MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-95.74%vs Biotechnology peers
Operating Cash Flow (TTM)
-131.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-75.38MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
25.42MUSDFY2025 · Dec 31, 2025Operating Income
-157.90MUSDvs all stocks (USD)
Pre-tax Income
-142.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
924.00KUSDFY2025 · Dec 31, 2025Net Income
-143.75MUSDFY2025 · Dec 31, 2025EBIT
-157.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-153.80MUSDFY2025 · Dec 31, 2025Research & Development
142.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.05MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.07MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.47USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.47USDFY2025 · Dec 31, 2025Basic Shares Outstanding
41.37MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
41.37MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-143.75MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-136.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-137.60MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
94.34MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-143.75MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.10MUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.61MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.50MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.80MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.22MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.04MUSDFY2025 · Dec 31, 2025Purchase of Investments
-141.61MUSDFY2025 · Dec 31, 2025Sale of Investments
259.46MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
116.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
38.82MSharesUpdated Jul 19, 2026Float Shares
21.41MSharesUpdated Jul 19, 2026Shares Short
2.11MSharesUpdated Jul 19, 2026Short Ratio
7.04daysvs all stocks
Short % of Shares Outstanding
8.45%vs all stocks
% Held by Insiders
12.31%vs all stocks
% Held by Institutions
78.89%vs all stocks
Total Cash (MRQ)
254.86MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.07USDUpdated Jul 19, 2026Total Debt (MRQ)
49.75MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1837xvs Biotechnology peers
Current Ratio (MRQ)
13.90xvs Biotechnology peers
Book Value per Share (MRQ)
7.52USDUpdated Jul 19, 2026Total Assets
377.38MUSDvs all stocks (USD)
Total Current Assets
306.25MUSDFY2025 · Dec 31, 2025Total Liabilities
71.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
71.13MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
46.79MUSDFY2025 · Dec 31, 2025Total Current Liabilities
24.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
90.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
205.30MUSDFY2025 · Dec 31, 2025Accounts Payable
2.29MUSDFY2025 · Dec 31, 2025Short-term Debt
4.14MUSDFY2025 · Dec 31, 2025Deferred Revenue
342.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.17MUSDFY2025 · Dec 31, 2025Long-term Debt
46.79MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-273.09MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
306.13MUSDvs all stocks (USD)
52-Week Low
4.93USDUpdated Jul 19, 202652-Week High
16.45USDUpdated Jul 19, 202652-Week Change
12.21%vs all stocks
Beta
-0.2640xvs all stocks
50-Day MA
7.22USDUpdated Jul 19, 2026200-Day MA
9.62USDUpdated Jul 19, 2026Avg 10-Day Volume
407.55KSharesUpdated Jul 19, 2026Avg 30-Day Volume
339.65KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.00USDUpdated Jul 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -4834.6%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -48.35Industry median: -0.34Industry P5: -43.55Peers compared: 261
Price-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.92Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 46.61Revenue Growth YoY: -0.96
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 13.90Altman Z-Score: 0.82
Financial Health
Altman Z-Score 0.82: distress zoneCritical
Altman Z-Score: 0.82
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $267.47M, lower than 95% of all stocks globallySignificant
Market cap (USD): 267,474,044Global P5: 269,387,740.27
Revenue is $5.74M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,738,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Wave Life Sciences Ltd.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Sealsq Corp
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Enovix Corporation
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC